Key result
Finerenone plus SGLT2i is linked to ~80% fewer major adverse kidney events versus monotherapy.
Why the study?
SGLT2 inhibitors and finerenone each improve kidney and cardiovascular outcomes in CKD patients, but the comparative effects of combined therapy versus monotherapy are unclear.
Does combined therapy with finerenone and SGLT2 inhibitors reduce major adverse kidney events in adults with chronic kidney disease compared to monotherapy?
Cohort (n=47,743)
Yes
Does combined therapy with finerenone and SGLT2 inhibitors reduce major adverse kidney events in adults with chronic kidney disease compared to monotherapy?
Combined therapy with finerenone and SGLT2 inhibitors is associated with a significantly lower risk of major adverse kidney events and all-cause mortality in CKD patients compared to monotherapy, though with an increased risk of hyperkalemia.
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and finerenone each improve kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD). This study compares the association between combined therapy versus monotherapy with SGLT2i or finerenone and the kidney, cardiovascular and mortality outcomes in CKD patients. METHODS: This retrospective cohort study included adults ≥18 years with CKD between 9 July 2021, and 30 November 2023 from multiple centers in the USA, utilizing the TriNetX database. Exposures included treatment with finerenone, SGLT2i or a combination of both. The primary outcome was major adverse kidney events (MAKE). Secondary outcomes included all-cause mortality, major adverse cardiac events (MACE) and end-stage renal disease (ESRD). RESULTS: A total of 853 patients were included in the combined group [mean (±standard deviation) age, 66.7 ± 11.4 years; 34.9% female], 942 in the finerenone group (mean age, 68.2 ± 11.4 years; 45.8% female) and 45 948 in the SGLT2i group (mean age, 70.2 ± 11.8 years; 41.4% female). After matching, the combined group had less MAKE compared with finerenone monotherapy [adjusted hazard ratio (aHR) 0.20; 95% confidence interval (CI) 0.09-0.45] or SGLT2i monotherapy (aHR 0.44; 95% CI 0.22-0.89). The hazards of all-cause mortality and ESRD were also lower in the combined group compared with either finerenone or SGLT2i alone, while hazard of MACE was similar between the combined and monotherapy groups. The combined group had higher risk of hyperkalemia compared with SGLT2i monotherapy (aHR = 1.36; 95% CI 1.08-1.71). CONCLUSION: Combined therapy with finerenone and SGLT2i is associated with less MAKE and all-cause mortality in CKD patients compared with monotherapy. However, the risk of hyperkalemia with finerenone warrants caution.
No takes yet. Share an insight, caveat, or question.
Chuang et al. (2025) conducted a cohort in chronic kidney disease (CKD) (n=47,743). Combined therapy with finerenone and SGLT2i vs. Finerenone monotherapy or SGLT2i monotherapy was evaluated on major adverse kidney events (MAKE) (aHR 0.20, 95% CI 0.09-0.45). Combined therapy with finerenone and SGLT2 inhibitors was associated with a lower risk of major adverse kidney events compared with finerenone (aHR 0.20; 95% CI 0.09-0.45) or SGLT2i monotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: